ライフサイエンスコーパス: hepatitis C virus

1 rictions for people co-infected with HIV and hepatitis C virus.

2 compounds showed antiviral activity against hepatitis C virus.

3 be avoided in black patients with genotype 1 hepatitis C virus.

4 a performed well in patients with cACLD with hepatitis C virus and alcoholic and nonalcoholic steatoh

5 We demonstrate that, in sharp contrast to hepatitis C virus and human immunodeficiency virus patie

6 Although the related flaviviruses hepatitis C virus and human pegivirus (formerly named GB

7 Understanding how hepatitis C virus and other flaviviruses interact with t

8 ople have been estimated to be infected with hepatitis C virus, and many more are at risk for infecti

9 a from patients with AIH, hepatitis B virus, hepatitis C virus, and nonalcoholic steatohepatitis.

10 BACKGROUND & AIMS: Patients with hepatitis C virus-associated cirrhosis and clinical sign

11 enter prospective study of 226 patients with hepatitis C virus-associated cirrhosis and CSPH who had

12 lticenter prospective study of patients with hepatitis C virus-associated cirrhosis, an SVR to all-or

13 a4 that might explain its negative effect on hepatitis C virus clearance.

14 r 24 weeks in 9 human immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after

15 or ultrasensitive and selective detection of hepatitis C virus core antigen (HCV) have been investiga

16 Testing for hepatitis C virus core antigen (HCVcAg) is a potential a

17 substratum to load antibody for detection of hepatitis C virus core antigen.

18 SV) 1 and 2, human immunodeficiency virus 1, hepatitis C virus, enterovirus 70, and variant Creutzfel

19 This issue provides a clinical overview of hepatitis C virus, focusing on transmission, prevention,

20 available North American sequences from five hepatitis C virus genes (E1, E2, NS2, NS4B, NS5B), with

21 MC647055/ritonavir + JNJ-56914845 in chronic hepatitis C virus genotype (GT)1-infected treatment-naiv

22 confidence interval, 86%-100%) patients with hepatitis C virus genotype 1 infection, 13 of 14 (93%; 9

23 6 weeks or less among patients with chronic hepatitis C virus genotype 1 infection.

24 rated and effective, particularly those with hepatitis C virus genotype 1 or 2 infection.

25 eened 45 316 publicly available sequences of hepatitis C virus genotype 1a for location and genotype,

26 highly effective in adolescents with chronic hepatitis C virus genotype 2 or 3 infection.

27 and ribavirin in adolescents aged 12-17 with hepatitis C virus genotype 2 or 3.

28 Patients with hepatitis C virus genotype 3 infection with prior treatm

29 caprevir/pibrentasvir (G/P) in patients with hepatitis C virus genotype 3 infection with prior treatm

30 Chronic infections with hepatitis C virus (HCV) and HIV are highly prevalent in

31 Persons co-infected with hepatitis C virus (HCV) and HIV.

32 Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus

33 steatosis (HS) is common in individuals with hepatitis C virus (HCV) and human immunodeficiency virus

34 Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained

35 [BPA], and patient solicitation), evaluated hepatitis C virus (HCV) antibody testing, diagnosis, and

36 afety and efficacy in treating patients with hepatitis C virus (HCV) awaiting liver transplant (LT).

37 Hepatitis C virus (HCV) causes chronic infections in at

38 Hepatitis C virus (HCV) causes mixed cryoglobulinemia (M

39 urrent standard of care for the treatment of hepatitis C virus (HCV) consists of interferon-free dire

40 lines were genetically engineered to display Hepatitis C virus (HCV) core antigen linked to gold bind

41 Hepatitis C virus (HCV) cure rates have been similar in

42 In this report, we demonstrated that hepatitis C virus (HCV) depleted TRAF6 from its host cel

43 Hepatitis C virus (HCV) displays a restricted host speci

44 st immune system to the efficacy of new anti-hepatitis C virus (HCV) drugs is unclear.

45 recently been identified as an inhibitor of hepatitis C virus (HCV) entry.

46 we longitudinally sampled and sequenced the hepatitis C virus (HCV) envelope genome region (1,680 nu

47 ey population affected by the global HIV and hepatitis C virus (HCV) epidemics.

48 The Asia-Pacific region has disparate hepatitis C virus (HCV) epidemiology, with prevalence ra

49 Hepatitis C virus (HCV) establishes persistent infection

50 Hepatitis C virus (HCV) exists as a lipoprotein-virus hy

51 cessary; however, PEP is not recommended for hepatitis C virus (HCV) exposures.

52 Patients chronically infected with hepatitis C virus (HCV) frequently develop mixed cryoglo

53 S5A, which is involved in replication of the hepatitis C virus (HCV) genome, presumably via membranou

54 r + DSV) +/- ribavirin (RBV) is approved for hepatitis C virus (HCV) genotype 1 (GT1) treatment in HI

55 n the United States for treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infections, as

56 The optimal retreatment strategy for hepatitis C virus (HCV) genotype 1-infected patients who

57 BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) genotype 2 have high rates of re

58 Hepatitis C virus (HCV) genotype 4 infection is most com

59 pproved treatment regimens for patients with hepatitis C virus (HCV) genotypes (GTs) 2 and 3 contain

60 ive samples, linearity, and performance with hepatitis C virus (HCV) genotypes were evaluated.

61 Current national hepatitis C virus (HCV) guidelines do not recommend the

62 B-cell infection by hepatitis C virus (HCV) has been a controversial topic.

63 Hepatitis C virus (HCV) has been shown to induce autopha

64 Hepatitis C virus (HCV) has dominated the field of hepat

65 atients chronically infected with genotype 3 hepatitis C virus (HCV) have faster disease progression

66 is study examined the interactions among the hepatitis C virus (HCV) helicase and RLR helicases in li

67 miR-122, a pro-viral hepatitis C virus (HCV) host factor, binds and recruits

68 changes that occur upon prolonged passage of hepatitis C virus (HCV) in human hepatoma cells in an ex

69 tly-acting antivirals has been advocated for Hepatitis C Virus (HCV) in people who inject drugs (PWID

70 dynamics, and phenotypic diversification of hepatitis C virus (HCV) in the course of 200 passages in

71 We determined temporal trends (1985-2011) in hepatitis C virus (HCV) incidence and associated behavio

72 Hepatitis C virus (HCV) infection affects over 130 milli

73 ing antiviral agents that can cure a chronic hepatitis C virus (HCV) infection after 8-12 weeks of da

74 recommended regimens to treat patients with hepatitis C virus (HCV) infection after liver transplant

75 Treatment of chronic hepatitis C virus (HCV) infection after renal allograft

76 known of an epidemic of sexually transmitted hepatitis C virus (HCV) infection among human immunodefi

77 response (SVR) on outcomes of patients with hepatitis C virus (HCV) infection and compensated cirrho

78 lecaprevir and pibrentasvir in patients with hepatitis C virus (HCV) infection and compensated cirrho

79 The association between hepatitis C virus (HCV) infection and end-stage renal di

80 egimen for 12 weeks in patients with chronic hepatitis C virus (HCV) infection and stage 4-5 chronic

81 ociations between hepatitis B virus (HBV) or hepatitis C virus (HCV) infection and the development of

82 AIT cells in livers of patients with chronic hepatitis C virus (HCV) infection and their fate after a

83 Outcomes of hepatitis C virus (HCV) infection and treatment depend o

84 pment of drugs targeting the early stages of Hepatitis C virus (HCV) infection are hampered by the la

85 tive studies of the outcomes associated with hepatitis C virus (HCV) infection are rare and critical

86 have demonstrated that patients with chronic hepatitis C virus (HCV) infection associated HCC survive

87 nbiased genome-to-genome analysis in chronic hepatitis C virus (HCV) infection confirms the innate an

88 Whether chronic hepatitis C virus (HCV) infection decreases humoral and

89 with persistent and spontaneously resolving hepatitis C virus (HCV) infection during the acute phase

90 Hepatitis C virus (HCV) infection has been associated wi

91 In the United States, hepatitis C virus (HCV) infection has increased among yo

92 Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection has resulted in high r

93 acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstrated high

94 BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) infection have high rates of sus

95 of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infection in kidney transplant r

96 of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infection in kidney transplant r

97 ffective, and pan-genotypic regimen to treat hepatitis C virus (HCV) infection in patients coinfected

98 ng antiviral (DAA) medications, treatment of hepatitis C virus (HCV) infection in renal transplant re

99 asvir-sofosbuvir is effective at eradicating hepatitis C virus (HCV) infection in the general populat

100 In a previous study, we have shown that hepatitis C virus (HCV) infection induces epithelial-mes

101 Hepatitis C virus (HCV) infection is a common risk facto

102 BACKGROUND & AIMS: Chronic hepatitis C virus (HCV) infection is a major burden on i

103 Hepatitis C virus (HCV) infection is a major cause of li

104 Hepatitis C virus (HCV) infection is a major risk factor

105 Chronic hepatitis C virus (HCV) infection is associated with imp

106 Direct-acting antiviral treatment for hepatitis C virus (HCV) infection is costly and does not

107 efficacy of antiviral treatment for chronic hepatitis C virus (HCV) infection is determined by measu

108 Chronic hepatitis C virus (HCV) infection is more prevalent amon

109 Hepatitis C virus (HCV) infection is prevalent in the re

110 Hepatitis C virus (HCV) infection is the most common chr

111 A vaccine that prevents hepatitis C virus (HCV) infection is urgently needed to

112 The mechanism of how chronic hepatitis C virus (HCV) infection leads to such a high r

113 immunodeficiency virus (HIV) and/or chronic hepatitis C virus (HCV) infection may be prescribed stat

114 s stage influences the CHF risk or if HIV or hepatitis C virus (HCV) infection modifies this associat

115 Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection promote NHL in HIV-inf

116 The immuno-pathogenic mechanisms of chronic hepatitis C virus (HCV) infection remain to be elucidate

117 lines now recommend that patients with acute hepatitis C virus (HCV) infection should be treated with

118 e the relationships of hepatitis B (HBV) and hepatitis C virus (HCV) infection to age-related catarac

119 The predisposition of patients with Hepatitis C virus (HCV) infection to hepatocellular carc

120 atocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) infection treated with direct-ac

121 Historically, acute hepatitis C virus (HCV) infection was treated with short

122 People with hepatitis C virus (HCV) infection who have failed treatm

123 Treatment of genotype 1 hepatitis C virus (HCV) infection with combination direc

124 lete regimen for adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or w

125 ivirals (DAAs) effectively eradicate chronic hepatitis C virus (HCV) infection, although HCV genotype

126 Fibrosis is associated with chronic hepatitis C virus (HCV) infection, although the mechanis

127 ins are detected in 40%-60% of patients with hepatitis C virus (HCV) infection, and overt cryoglobuli

128 e the availability of curative treatment for hepatitis C virus (HCV) infection, because of cost, trea

129 ptor proteins AP1 and AP2, are essential for hepatitis C virus (HCV) infection, but the underlying me

130 h cure rate in treated patients with chronic hepatitis C virus (HCV) infection, but this still leaves

131 For an efficient control of hepatitis C virus (HCV) infection, cytotoxic T cells (CT

132 ent of more effective drugs for treatment of hepatitis C virus (HCV) infection, there has been an inc

133 central role in the pathogenesis of chronic hepatitis C virus (HCV) infection.

134 esent the standard of care for patients with hepatitis C virus (HCV) infection.

135 agents (DAAs) are used increasingly to treat hepatitis C virus (HCV) infection.

136 have been approved for children with chronic hepatitis C virus (HCV) infection.

137 eradication to >90% in patients with chronic hepatitis C virus (HCV) infection.

138 protease inhibitor GS-9857, in patients with hepatitis C virus (HCV) infection.

139 patients with inherited blood disorders and hepatitis C virus (HCV) infection.

140 Outbreaks of hepatitis C virus (HCV) infections are associated with u

141 artments (EDs) seem to be able to detect new hepatitis C virus (HCV) infections at a high rate, but i

142 All patients with chronic hepatitis C virus (HCV) infections can and should be tre

143 Hepatitis C virus (HCV) infects 200 million people globa

144 Hepatitis C virus (HCV) is a global health concern that

145 Hepatitis C virus (HCV) is a single-stranded positive-se

146 Hepatitis C virus (HCV) is a unique enveloped virus that

147 The p7 protein of hepatitis C virus (HCV) is an intracellular ion channel

148 Occult infection with hepatitis C virus (HCV) is defined as the presence of th

149 itious targets for global control of HIV and hepatitis C virus (HCV) is low levels of awareness of in

150 Viral load monitoring for hepatitis C virus (HCV) is necessary to diagnose infecti

151 Hepatitis C virus (HCV) is one of the leading causes of

152 Chronic infection with hepatitis C virus (HCV) is one of the main causes of hep

153 Vertical transmission of hepatitis C virus (HCV) is the most common route of pedi

154 Hepatitis C virus (HCV) is unique among RNA viruses in i

155 ontributed to increased understanding of the hepatitis C virus (HCV) life cycle.

156 formed by glycoproteins E1 and E2 within the hepatitis C virus (HCV) lipid envelope is a potential va

157 Hepatitis C virus (HCV) nonstructural protein 5A (NS5A)

158 nt pan-genotype and macrocyclic inhibitor of hepatitis C virus (HCV) NS3/4A protease and was develope

159 BACKGROUND & AIMS: Inhibitors of the hepatitis C virus (HCV) NS5A protein are a key component

160 The hepatitis C virus (HCV) NS5B replicase is a prime target

161 Hepatitis C virus (HCV) often causes persistent infectio

162 enib with alternative therapies according to hepatitis C virus (HCV) or hepatitis B virus (HBV) statu

163 rotein synthesis to directly incorporate the hepatitis C virus (HCV) p7 protein into supported lipid

164 s an urgent need for a vaccine to combat the hepatitis C virus (HCV) pandemic, and induction of broad

165 rd-of-care treatment of chronically infected hepatitis C virus (HCV) patients involves direct-acting

166 inhibitors, particularly those of HIV-1 and hepatitis C virus (HCV) protease, revealed a plethora of

167 Hepatitis C virus (HCV) reactivation in patients receivi

168 to assess human immunodeficiency virus (HIV)/hepatitis C virus (HCV) real-world treatment outcomes.

169 pite recent advances in therapeutic options, hepatitis C virus (HCV) remains a severe global disease

170 Hepatitis C virus (HCV) remains the leading indication f

171 , exhibit potent inhibitory activity against hepatitis C virus (HCV) replication in genotype 1b Con 1

172 croRNAs (miRNAs) have been shown to regulate hepatitis C virus (HCV) replication, yet a systematic in

173 miR-122 is an important host factor for hepatitis C virus (HCV) replication.

174 Reliance on hepatitis C virus (HCV) replicon systems and protein-bas

175 Hepatitis C virus (HCV) requires multiple receptors for

176 polymerase that catalyzes replication of the hepatitis C virus (HCV) RNA genome and therefore is cent

177 The affordable and reliable detection of Hepatitis C Virus (HCV) RNA is a cornerstone in the mana

178 Point-of-care hepatitis C virus (HCV) RNA testing offers an advantage

179 Targeted hepatitis C virus (HCV) screening is recommended.

180 an electronic health record-based prompt on hepatitis C virus (HCV) screening rates in baby boomers

181 ntive Services Task Force recommend one-time hepatitis C virus (HCV) testing for persons born during

182 ntrol and Prevention (CDC) recommends 1-time hepatitis C virus (HCV) testing in the 1945-1965 birth c

183 Highly effective hepatitis C virus (HCV) therapies have spurred a scale-u

184 There is a need for hepatitis C virus (HCV) therapies with excellent efficac

185 New hepatitis C virus (HCV) therapies with pan-genotypic eff

186 Rapid improvements in hepatitis C virus (HCV) therapy have led to the approval

187 out substitutions that mediate resistance of hepatitis C virus (HCV) to direct-acting antivirals (DAA

188 ral direct-acting antivirals has altered the hepatitis C virus (HCV) treatment paradigm for both pre-

189 Cost-effectiveness analyses (CEAs) of hepatitis C virus (HCV) treatment strategies have become

190 ivirals (DAAs) have changed the landscape of hepatitis C virus (HCV) treatment, but chronic hepatitis

191 Eradication of hepatitis C virus (HCV) using direct-acting agents (DAA)

192 e models has been an obstacle for developing hepatitis C virus (HCV) vaccines and affordable antivira

193 Clearance of hepatitis C virus (HCV) via antiviral treatment changes

194 The association of hepatitis C virus (HCV) with non-Hodgkin's lymphoma (NHL

195 Hepatitis C virus (HCV)(+) donors represent an effective

196 ect drugs (PWID); and the prevalence of HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) amo

197 ected by human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV).

198 for detection of cirrhosis in patients with hepatitis C virus (HCV), hepatitis B virus (HBV), NAFLD,

199 th decompensated cirrhosis (DC) secondary to hepatitis C virus (HCV), is associated with improved hep

200 RNA (+RNA) viruses including human pathogens hepatitis C virus (HCV), Severe acute respiratory syndro

201 burden posed by hepatitis B virus (HBV) and hepatitis C virus (HCV), to learn from each other's expe

202 with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), we assessed fibrosis progressio

203 cohort of human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients treated with

204 was cloned from T cells that expanded when a hepatitis C virus (HCV)-infected HLA-A2(-) individual re

205 A) is the nation's largest care provider for hepatitis C virus (HCV)-infected patients and is uniquel

206 k of chronic kidney disease (CKD) in chronic hepatitis C virus (HCV)-infected patients and the incide

207 Hepatitis C virus (HCV)-infected patients with chronic k

208 d high efficacy, safety, and tolerability in hepatitis C virus (HCV)-infected patients.

209 We prospectively evaluated 251 chronic hepatitis C virus (HCV)-infected subjects (31% human imm

210 Within hepatitis C virus (HCV)-like IRES elements, the sub-doma

211 Hepatitis C virus (HCV)-mediated chronic liver disease i

212 Identifying hepatitis C virus (HCV)-positive persons at high risk of

213 k of acute myocardial infarction (AMI) among hepatitis C virus (HCV)-positive versus HCV-negative per

214 (NAFLD-HCC) and to compare them to those of hepatitis C virus (HCV)-related HCC.

215 Guidelines recommend that patients with hepatitis C virus (HCV)-related liver disease be treated

216 The antiviral effects of hepatitis C virus (HCV)-specific CD8 T cells have been s

217 on individuals are chronically infected with hepatitis C virus (HCV).

218 oRNA-122 is an important host factor for the hepatitis C virus (HCV).

219 cy virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV).

220 1 million people worldwide are infected with hepatitis C virus (HCV).

221 is required for infection of hepatocytes by hepatitis C virus (HCV).

222 s) after infection with cell culture-derived hepatitis C virus (HCV).

223 is required for infection of hepatocytes by hepatitis C virus (HCV).

224 IM-1 is important for efficient infection by hepatitis C virus (HCV).

225 l survival benefit for persons infected with hepatitis C virus (HCV).

226 mortality in patients with cirrhosis due to hepatitis C virus (HCV).

227 related to either hepatitis B virus (HBV) or hepatitis C virus (HCV).

228 n of antiretroviral therapy in patients with hepatitis C virus (HCV)/HIV-1 coinfection.

229 ly observed in individuals infected with the hepatitis C virus (HCV); however, the underlying molecul

230 Hepatitis C viruses (HCV) encode a helicase enzyme that

231 A recombinant strain HCV1 (hepatitis C virus [HCV] genotype 1a) gpE1/gpE2 (E1E2) va

232 igh rates of sustained virological response (hepatitis C virus [HCV] RNA <15 IU/mL) at post-treatment

233 serostatus (+ or -: hepatitis B core [HBc], hepatitis C virus [HCV], Epstein-Barr virus [EBV], or cy

234 st a wide variety of viruses, including HIV, hepatitis C virus, hepatitis B virus, enterovirus 71, in

235 as well as profound antiviral effect against hepatitis C virus, human rhinovirus, and coxsackievirus

236 or without ribavirin as treatment of chronic hepatitis C virus in solid organ transplant recipients a

237 AA) therapies are effective in patients with hepatitis C virus-induced cryoglobulinemia vasculitis (H

238 hepatitis B virus (HBV) has been reported in hepatitis C virus-infected individuals receiving direct-

239 We identified 21,095 hepatitis C virus-infected patients (11,029 [52%] white,

240 HIV-negative patients with cancer (n = 53), hepatitis C virus-infected patients (n = 17), and health

241 the PITER cohort (representative of Italian hepatitis C virus-infected patients in care).

242 ir (LDV/SOF) can be considered in genotype 1 hepatitis C virus-infected patients who are treatment-na

243 treatment policies in a real-life cohort of hepatitis C virus-infected policy 1, "universal," treat

244 his retrospective evaluation included 62,290 hepatitis C virus-infected veterans completing oral DAA

245 n (54.1%, P = 0.001), had lower incidence of hepatitis C virus infection (4.9%, P = 0.001) and longer

246 old-especially those born in the peak era of hepatitis C virus infection and among whites/Caucasians.

247 preclinical candidates for the treatment of hepatitis C virus infection and as probes to study hepat

248 called mixed cryoglobulinemia and is seen in hepatitis C virus infection and systemic diseases such a

249 Children with chronic hepatitis C virus infection have limited treatment optio

250 antiviral drugs for the treatment of chronic hepatitis C virus infection have reduced mortality and t

251 s after DAA therapy in patients with chronic hepatitis C virus infection in the context of the immune

252 Chronic hepatitis C virus infection is associated with significa

253 Chronic hepatitis C virus infection is well-recognized as a comm

254 report a case series of three patients with hepatitis C virus infection who all presented with sever

255 djusted for age, race or ethnicity, smoking, hepatitis C virus infection, alcohol use disorders, drug

256 and well tolerated in patients with chronic hepatitis C virus infection, including those with compen

257 ) to interferon-based treatments for chronic hepatitis C virus infection, whereas Asian race was asso

258 New Zealand of 197 patients with genotype 1 hepatitis C virus infection, with or without compensated

259 revolutionized care of patients with chronic hepatitis C virus infection.

260 iral cytokine, are also less likely to clear hepatitis C virus infection.

261 us infection; 29.1% (95% CI: 23.6-34.5%) for hepatitis C virus infection; 33.9% (95% CI: 24.3-43.5%)

262 through the control of hepatitis B virus and hepatitis C virus infections by vaccination and treatmen

263 epatitis, especially chronic hepatitis B and hepatitis C virus infections.

264 ture-based design of HCV vaccines.IMPORTANCE Hepatitis C virus is a leading cause of liver disease an

265 lization of replication complexes.IMPORTANCE Hepatitis C virus is an important human pathogen.

266 stimulation during persistent infection with hepatitis C virus is associated with continuous activati

267 Hepatitis C virus is capable of establishing a lifelong

268 listed women differed in age (58 vs 57), non-hepatitis C virus listing diagnoses (69% vs 56%), hepati

269 29382 young persons currently infected with hepatitis C virus lived >10 miles from a syringe service

270 itis C virus-positive (50.9-57.9 years) than hepatitis C virus-negative (51.3-54.3 years) registrants

271 In hepatitis C virus-negative patients, aging trends were d

272 avage of four novel substrate motifs for the hepatitis C virus NS3/4 protease using an in vivo assay.

273 The mechanisms by which infectious hepatitis C virus particles are assembled and released f

274 tis C virus infection and as probes to study hepatitis C virus pathogenesis and host-virus interactio

275 We conducted a retrospective cohort study of hepatitis C virus patients who were treated with DAA in

276 ood and tissue donors, persons infected with hepatitis C virus, persons with elevated alanine aminotr

277 s to those of the initiation complex for the hepatitis C virus polymerase.

278 th cold ischemic time >12 hours, livers from hepatitis C virus positive donors, livers from donation

279 5.7 years, with a more prominent increase in hepatitis C virus-positive (50.9-57.9 years) than hepati

280 ed from 2002 to 2014, driven by aging of the hepatitis C virus-positive cohort and increased prevalen

281 In particular, how and when hepatitis C virus reached extraordinary prevalence in sp

282 The protease NS3/4A from hepatitis C virus redistributes the complexes RIG-I/MAVS

283 Indeed, increased SALL4 expression in hepatitis C virus-related HCCs correlated with demethyla

284 further show that kinesin knockdown inhibits hepatitis-C virus replication in hepatocytes, likely bec

285 hepatitis before and after implementation of hepatitis C virus screening was assessed.

286 ssion, all from an active IVDU donor who was hepatitis C virus seronegative at time of donation, but

287 ceiving irrelevant T cells redirected toward hepatitis C virus-specific TCRs.

288 r End-Stage Liver Disease at transplant, and hepatitis C virus status.

289 ify the transmission dynamics that drive the hepatitis C virus subtypes 4a (HCV4a) and 4d (HCV4d) epi

290 There were 3 cases of unexpected hepatitis C virus transmission, all from an active IVDU

291 nce of some countries not following the 2016 hepatitis C virus treatment guidelines by the European A

292 rejection (n = 2 KT, 4 LT) occurred, during hepatitis C virus treatment in 4 and after cessation of

293 Extending hepatitis C virus treatment to patients in any fibrosis

294 Hepatitis C virus was the leading cause of hepatocellula

295 The Biochain ELISA kit for Human Hepatitis C Virus was used for antibody assay.

296 involved in the assembly and release of the hepatitis C virus, was determined from proteins expresse

297 the setting of viral hepatitis, particularly hepatitis C virus, where sustained viral response has be

298 ral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or m

299 ategy for patients chronically infected with hepatitis C virus who experience virologic failure after

300 dations on the care of patients with chronic hepatitis C virus who have achieved SVR.